5-lipoxygenase inhibitor zileuton attenuates ischemic brain damage: involvement of matrix metalloproteinase 9

Authors: Tu, Xian-Kun¹; Yang, Wei-Zhong²; Shi, Song-Sheng¹; Chen, Chun-Mei¹; Wang, Chun-Hua¹

Source: Neurological Research, Volume 31, Number 8, October 2009 , pp. 848-852(5)

Purchase options

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$51.00 plus tax Refund Policy

More about this publication?

Fast track publication facility now available, please click here for further information

Authors wishing to cite fast track papers should give the journal name and the article DOI. This will enable reference linking via CrossRef and allow forward and backward citation tracking systems to associate the fast track citation with the final journal reference.
Editorial Board
Information for Authors
Subscribe to this Title
Terms & Conditions
Online submission site

More like this?

In this: publication
By this: publisher
In this Subject: Neurology & Psychiatry
By this author: Tu, Xian-Kun ; Yang, Wei-Zhong ; Shi, Song-Sheng ; Chen, Chun-Mei ; Wang, Chun-Hua

Content Key:

- Free

- New

- Open Access

- Subscribed

- Free Trial

Abstract:

Objectives: Cerebral ischemia causes an increased expression and activation of 5-lipoxygenase (5-LOX) and matrix metalloproteinase 9 (MMP-9). Recent works demonstrated that the selective 5-LOX inhibitor zileuton down-regulates MMP-9 expression in vascular diseases and cancer. In the present work, we first studied the neuroprotective effect of zileuton on focal cerebral ischemia in rats and further investigated the effect of zileuton on the expression of 5-LOX and MMP-9 in ischemic brain.

Methods: Adult Sprague-Dawley rats underwent permanent middle cerebral artery occlusion (pMCAO). The rats then received treatment with zileuton 5, 10 or 50 mg/kg or vehicle. Cerebral water content and infarct volume were measured 24 hours after pMCAO. Expression of 5-LOX messenger RNA (mRNA) and MMP-9 mRNA were determined by reverse transcription polymerase chain reaction. The levels of the proform and the active form of MMP-9 were detected by gelatin zymography.

Results: Oral treatment of zileuton at 10 or 50 mg/kg significantly reduced cerebral water content and infarct volume. It also down-regulated the expression of 5-LOX mRNA and MMP-9 mRNA. Zileuton at 50 mg/kg could inhibit the active form of MMP-9.

Conclusion: These results suggest that selective 5-LOX inhibitor zileuton attenuates ischemic brain damage in rats, which may be partly associated with MMP-9 inhibition.

Keywords: CEREBRAL ISCHEMIA; 5-LIPOXYGENASE; MATRIX METALLOPROTEINASE-9; NEUROPROTECTION; ZILEUTON

Document Type: Research article

DOI: 10.1179/174313209X403913

Affiliations: 1: Department of Neurosurgery, Affiliated Union Hospital, Fujian Medical University, Fuzhou, Fujian, China 2: Department of Neurosurgery, Affiliated Union Hospital, Fujian Medical University, 29# Xinquan Road, Fuzhou, Fujian 350001, China;, Email: unionyangwz@hotmail.com